These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 38066643)

  • 1. Leveraging a disulfidptosis‑related lncRNAs signature for predicting the prognosis and immunotherapy of glioma.
    Chen D; Li Q; Xu Y; Wei Y; Li J; Zhu X; Li H; Lu Y; Liu X; Yan D
    Cancer Cell Int; 2023 Dec; 23(1):316. PubMed ID: 38066643
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Construction and Validation of a Reliable Disulfidptosis-Related LncRNAs Signature of the Subtype, Prognostic, and Immune Landscape in Colon Cancer.
    Dong X; Liao P; Liu X; Yang Z; Wang Y; Zhong W; Wang B
    Int J Mol Sci; 2023 Aug; 24(16):. PubMed ID: 37629096
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel disulfidptosis-related lncRNAs signature for predicting survival and immune response in hepatocellular carcinoma.
    Guo Z; Xie Y; Zhang L; Liu S; Jiang W
    Aging (Albany NY); 2024 Jan; 16(1):267-284. PubMed ID: 38180745
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comprehensive Analysis of Disulfidptosis-Related LncRNAs in Molecular Classification, Immune Microenvironment Characterization and Prognosis of Gastric Cancer.
    Kang K; Li X; Peng Y; Zhou Y
    Biomedicines; 2023 Nov; 11(12):. PubMed ID: 38137387
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Construction and validation of a prognostic model for bladder cancer based on disulfidptosis-related lncRNAs.
    Yang X; Zhang Y; Liu J; Feng Y
    Medicine (Baltimore); 2024 Jul; 103(27):e38750. PubMed ID: 38968515
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of a novel disulfidptosis-related lncRNA signature for prognostic and immune response prediction in clear cell renal cell carcinoma.
    Wang N; Hu Y; Wang S; Xu Q; Jiao X; Wang Y; Yan L; Cao H; Shao F
    Sci Rep; 2024 Jan; 14(1):624. PubMed ID: 38182642
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development and validation of a novel disulfidptosis-related lncRNAs signature in patients with HPV-negative oral squamous cell carcinoma.
    Yang F; Niu X; Zhou M; Li W
    Sci Rep; 2024 Jun; 14(1):14436. PubMed ID: 38910181
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A disulfidptosis-related lncRNAs signature in hepatocellular carcinoma: prognostic prediction, tumor immune microenvironment and drug susceptibility.
    Liu Y; Meng J; Ruan X; Wei F; Zhang F; Qin X
    Sci Rep; 2024 Jan; 14(1):746. PubMed ID: 38185671
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Construction of a Novel Disulfidptosis-Related lncRNA Prognostic Signature in Pancreatic Cancer.
    Xing F; Qin Y; Xu J; Wang W; Zhang B
    Mol Biotechnol; 2023 Sep; ():. PubMed ID: 37733182
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Integrating bioinformatics and experimental validation to unveil disulfidptosis-related lncRNAs as prognostic biomarker and therapeutic target in hepatocellular carcinoma.
    Xu L; Chen S; Li Q; Chen X; Xu Y; Zhou Y; Li J; Guo Z; Xing J; Chen D
    Cancer Cell Int; 2024 Jan; 24(1):30. PubMed ID: 38218909
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Disulfidptosis‑related lncRNA prognosis model to predict survival therapeutic response prediction in lung adenocarcinoma.
    Sun X; Li J; Gao X; Huang Y; Pang Z; Lv L; Li H; Liu H; Zhu L
    Oncol Lett; 2024 Aug; 28(2):342. PubMed ID: 38855504
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel signature incorporating lipid metabolism- and immune-related genes to predict the prognosis and immune landscape in hepatocellular carcinoma.
    Yang T; Luo Y; Liu J; Liu F; Ma Z; Liu G; Li H; Wen J; Chen C; Zeng X
    Front Oncol; 2023; 13():1182434. PubMed ID: 37346073
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Signature Construction and Disulfidptosis-Related Molecular Cluster Identification for Better Prediction of Prognosis in Glioma.
    Zhuang Y; Chen J; Mai Z; Huang W; Zhong W
    J Mol Neurosci; 2024 Apr; 74(2):38. PubMed ID: 38573391
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A disulfidptosis-related lncRNA index predicting prognosis and the tumor microenvironment in colorectal cancer.
    Xiao L; Yin W; Chen X; Zhang X; Zhang C; Yu Z; Lü M
    Sci Rep; 2023 Nov; 13(1):20135. PubMed ID: 37978247
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Construction of disulfidptosis-related lncRNA signature for predicting the prognosis and immune escape in colon adenocarcinoma.
    Chen P; Yu J; Luo Q; Li J; Wang W
    BMC Gastroenterol; 2023 Nov; 23(1):382. PubMed ID: 37946148
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predicting colorectal cancer prognosis based on long noncoding RNAs of disulfidptosis genes.
    Wang KL; Chen KD; Tang WW; Chen ZP; Wang YJ; Shi GP; Chen YG
    World J Clin Oncol; 2024 Jan; 15(1):89-114. PubMed ID: 38292658
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bioinformatics-based analysis of the relationship between disulfidptosis and prognosis and treatment response in pancreatic cancer.
    Xiong Y; Kong X; Mei H; Wang J; Zhou S
    Sci Rep; 2023 Dec; 13(1):22218. PubMed ID: 38097783
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Construction of prognostic signature of breast cancer based on N7-Methylguanosine-Related LncRNAs and prediction of immune response.
    Cao J; Liang Y; Gu JJ; Huang Y; Wang B
    Front Genet; 2022; 13():991162. PubMed ID: 36353118
    [No Abstract]   [Full Text] [Related]  

  • 19. Identification of a novel defined inflammation-related long noncoding RNA signature contributes to predicting prognosis and distinction between the cold and hot tumors in bladder cancer.
    Xiong X; Chen C; Li X; Yang J; Zhang W; Wang X; Zhang H; Peng M; Li L; Luo P
    Front Oncol; 2023; 13():972558. PubMed ID: 37064115
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel signature of cuproptosis-related lncRNAs predicts prognosis in glioma: Evidence from bioinformatic analysis and experiments.
    Chen D; Xu Y; Gao X; Zhu X; Liu X; Yan D
    Front Pharmacol; 2023; 14():1158723. PubMed ID: 37101543
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.